Table 2.
Demographic, clinical, and laboratory data of patients at baseline (mean ± SD) n (%)
| Variable | Perihilar (n = 37) | Distal (n = 31) | Total (n = 68) |
| Age (yr) | 74.2 ± 10.5 | 72.4 ± 12.6 | 73.4 ± 11.5 |
| Sex (M/F) | 18/19 | 16/15 | 34/34 |
| Smoking | 13 (35.1) | 8 (25.8) | 21 (30.9) |
| Predisposing factor | 5 (13.5) | 1 (3.2) | 6 (8.8) |
| Family history of malignancy | 1 (2.7) | 4 (12.9) | 5 (7.4) |
| Clinical manifestations | |||
| Jaundice | 33 (89.2) | 26 (83.9) | 59 (86.8) |
| Abdominal pain | 16 (43.2) | 9 (29.0) | 25 (36.7) |
| Weight loss | 11 (29.7) | 8 (25.8) | 19 (27.9) |
| Fever | 0 (0) | 3 (9.7) | 3 (4.4) |
| Casual diagnosis | 0 (0) | 1 (3.2) | 1 (1.5) |
| Symptoms duration (mo) [median (range)] | 0.3 (0.01-12) | 0.5 (0.05-3.5) | 0.5 (0.01-12) |
| AST (IU/L) | 146 ± 104 | 129 ± 121 | 138 ± 111 |
| ALT (IU/L) | 211 ± 166 | 172 ± 139 | 193 ± 144 |
| γ-GT (IU/L) | 629 ± 377 | 811 ± 660 | 712 ± 529 |
| LDH (IU/L)a | 269 ± 180 | 169 ± 54 | 223 ± 174 |
| Albumin (g/dL) | 3.3 ± 0.4 | 3.2 ± 0.7 | 3.2 ± 0.6 |
| Bilirubin (mg/dL) | 15.6 ± 9.1 | 12.6 ± 9.5 | 14.2 ± 9.3 |
| Hemoglobin (g/dL) | 13.4 ± 1.4 | 12.7 ± 2.3 | 13.1 ± 1.9 |
| Platelets (× 1000/μL) | 257 ± 99 | 294 ± 103 | 274 ± 102 |
| Creatinine (mg/dL) | 0.8 ± 0.4 | 0.8 ± 0.3 | 0.8 ± 0.3 |
| CA 19-9 (IU/L) [median (range)]1 | 989 (2.9-65 920) | 87.6 (9-11 641) | 269 (2.9-65 920) |
1
Data available for 29 patients;
a
P = 0.005; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CA 19-9: Carbohydrate antigen 19-9; γ-GT: γ-glutamyltranspeptidase; LDH: Lactate dehydrogenase.